Md. biopharm to present data at European cancer conference

A Maryland biopharmaceutical firm’s research data has been accepted for an oral presentation at a conference in Europe. Rockville-based MacroGenics Inc. is scheduled to present data from the phase 1 clinical study of flotetuzumab on Sept. 10 at the European Society for Medical Oncology Annual Congress in Madrid, Spain. The phase 1 study is evaluating the safety and …

from http://thedailyrecord.com/2017/07/17/maryland-macrogenics-flotetuzumab-esmo-2017/

Advertisements

Author: Baltimore Checkbook

Best in consumer news and deals in Baltimore, MD.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s